Purchase Order 75N92B19P00029

The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. valued at $22,124.00 on September 20, 2019, with completion on September 27, 2019. The order is a firm fixed price, commercial item acquisition with no set-aside. Place of performance is Bethesda, Maryland. The purchase order procures genomic analysis instruments, consumables, or related bioinformatics products from 10X Genomics' single-cell and spatial transcriptomics...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. for $19,100.00 on August 23, 2018. No set-aside was applied. Place of performance is Bethesda, Maryland. The order was completed by August 22, 2019. Pricing was firm fixed price for commercial genomic analysis instruments, consumables, or reagents—10X Genomics' core product portfolio in single-cell and spatial transcriptomics platforms supplied to federal research agencies.

<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. valued at $20,509.00 on July 9, 2018, with completion on July 8, 2019. Performance took place in Pleasanton, California. The order was issued on a firm fixed price basis with no small business set-aside. The source does not specify the items or services procured.</p>

<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. valued at $24,119.00 on March 5, 2020, with completion by March 12, 2020. No set-aside was used. Performance occurred in Pleasanton, California. The order was issued on a firm fixed price basis for genomic analysis products and related supplies.</p>

<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. for $22,067.00 on June 4, 2019, with completion on June 18, 2019. No set-aside was used. Place of performance is Bethesda, Maryland. The order procures genomic analysis consumables and reagents under firm fixed price terms.</p>

The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. valued at $22,285.50 on September 10, 2019, with completion by September 9, 2020. No set-aside applied. Work is performed at Bethesda, Maryland. The order is priced on a firm fixed price basis for genomic analysis instruments, consumables, or reagents consistent with the vendor's product portfolio of single-cell and spatial transcriptomics platforms and associated kits.

<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. on August 20, 2018, with a ceiling value of $23,245.00 and a firm fixed price. No set-aside was used. Performance is located in Pleasanton, California. The order was ultimately completed on August 19, 2019.</p>

<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. valued at $20,290.50 on August 14, 2018, with completion on August 13, 2019. No set-aside was used. Performance occurred in Bethesda, Maryland. The order was for commercial genomic analysis instruments, consumables, or reagents supplied on a firm fixed-price basis by the manufacturer of single-cell and spatial transcriptomics platforms.</p>

<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to 10X Genomics, Inc. valued at $20,680.00 on September 4, 2019, with completion by September 11, 2019. No set-aside applied. Place of performance is Bethesda, Maryland. The order procures genomic analysis instruments, consumables, or bioinformatics software from 10X Genomics' Chromium and Xenium platforms for single-cell and spatial transcriptomics research applications.</p>

<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued a purchase order to 10X Genomics, Inc. valued at $21,581 with an award date of December 12, 2017. Work is performed in Bethesda, Maryland. The order covers genomic analysis instruments and consumables under a firm fixed price arrangement with a period of performance from December 12, 2017 through December 11, 2018.</p>